Moderate To Severe Plaque Psoriasis clinical trials

Explore recruiting moderate to severe plaque psoriasis clinical trials.

Recruiting moderate to severe plaque psoriasis studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Moderate To Severe Plaque Psoriasis trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of LY4100511 (DC-853) for the Treatment of Adult Participants with Moderate-to-Severe Plaque Psoriasis

Hungary, Poland, Czechia, Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Dose-Range Finding Study of ORKA-001 in Participants with Moderate-to-Severe Plaque Psoriasis

Germany, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A Multicenter, Randomized, Double-blind, Placebo- controlled, Parallel-group, Dose-ranging Study to Evaluate the Efficacy and Safety of DC-806 in Participants with Moderate to Severe Plaque Psoriasis

Spain, Poland, Hungary, Czechia, Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Randomized, Multicenter, Double-Blind, Placebo- and Active Comparator-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-279 in Subjects with Moderate-to-Severe Plaque Psoriasis

Poland, Italy, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Randomized, Multicenter, Double-Blind Trial to Evaluate the Efficacy, Safety, and Tolerability of Zasocitinib (TAK-279) Compared to Deucravacitinib in Participants With Moderate-to-Severe Plaque Psoriasis

Czechia, France, Bulgaria, Latvia, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Multicenter, Randomized, Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Deucravacitinib in Adolescent Subjects (12 years to less than 18 years) with Moderate to Severe Plaque Psoriasis

Germany, Romania, Italy, Belgium, Poland, Hungary +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Moderate To Severe Plaque Psoriasis trials by city

Moderate To Severe Plaque Psoriasis in Toronto Moderate To Severe Plaque Psoriasis in Vancouver Moderate To Severe Plaque Psoriasis in Montreal Moderate To Severe Plaque Psoriasis in Calgary Moderate To Severe Plaque Psoriasis in Edmonton Moderate To Severe Plaque Psoriasis in Ottawa Moderate To Severe Plaque Psoriasis in Winnipeg Moderate To Severe Plaque Psoriasis in Quebec City Moderate To Severe Plaque Psoriasis in Hamilton Moderate To Severe Plaque Psoriasis in Kitchener Moderate To Severe Plaque Psoriasis in London Moderate To Severe Plaque Psoriasis in Halifax Moderate To Severe Plaque Psoriasis in New York Moderate To Severe Plaque Psoriasis in Los Angeles Moderate To Severe Plaque Psoriasis in Chicago Moderate To Severe Plaque Psoriasis in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease